PL2132230T3 - Apoptotyczne przeciwciała anty-IgE wiążące IgE związaną z błoną - Google Patents

Apoptotyczne przeciwciała anty-IgE wiążące IgE związaną z błoną

Info

Publication number
PL2132230T3
PL2132230T3 PL08744179T PL08744179T PL2132230T3 PL 2132230 T3 PL2132230 T3 PL 2132230T3 PL 08744179 T PL08744179 T PL 08744179T PL 08744179 T PL08744179 T PL 08744179T PL 2132230 T3 PL2132230 T3 PL 2132230T3
Authority
PL
Poland
Prior art keywords
ige
membrane
antibodies binding
bound
apoptotic anti
Prior art date
Application number
PL08744179T
Other languages
English (en)
Inventor
Lawren Wu
Mercedesz Balazs
Hans Brightbill
Andrew Chan
Yvonne Chen
Anan Chuntharapai
Mark Dennis
Terence Wong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39709011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2132230(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PL2132230T3 publication Critical patent/PL2132230T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL08744179T 2007-03-22 2008-03-21 Apoptotyczne przeciwciała anty-IgE wiążące IgE związaną z błoną PL2132230T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89633907P 2007-03-22 2007-03-22
PCT/US2008/057819 WO2008116149A2 (en) 2007-03-22 2008-03-21 Apoptotic anti- ige antibodies binding the membrane-bound ige
EP08744179.6A EP2132230B1 (en) 2007-03-22 2008-03-21 Apoptotic anti-ige antibodies binding the membrane-bound ige

Publications (1)

Publication Number Publication Date
PL2132230T3 true PL2132230T3 (pl) 2014-09-30

Family

ID=39709011

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08744179T PL2132230T3 (pl) 2007-03-22 2008-03-21 Apoptotyczne przeciwciała anty-IgE wiążące IgE związaną z błoną

Country Status (31)

Country Link
US (6) US8071097B2 (pl)
EP (2) EP2132230B1 (pl)
JP (3) JP5723594B2 (pl)
KR (1) KR101555068B1 (pl)
CN (2) CN103554263B (pl)
AR (1) AR066198A1 (pl)
AU (1) AU2008228778B2 (pl)
BR (1) BRPI0808291A2 (pl)
CA (1) CA2681341A1 (pl)
CL (1) CL2008000839A1 (pl)
CO (1) CO6241138A2 (pl)
CR (1) CR11035A (pl)
CY (1) CY1115257T1 (pl)
DK (1) DK2132230T3 (pl)
EC (1) ECSP099645A (pl)
ES (1) ES2478242T3 (pl)
HR (1) HRP20140661T1 (pl)
IL (1) IL200752A0 (pl)
MA (1) MA31312B1 (pl)
MX (1) MX2009010092A (pl)
NZ (1) NZ580553A (pl)
PE (2) PE20140771A1 (pl)
PL (1) PL2132230T3 (pl)
PT (1) PT2132230E (pl)
RS (1) RS53402B (pl)
RU (1) RU2500686C2 (pl)
SI (1) SI2132230T1 (pl)
TW (1) TWI464178B (pl)
UA (1) UA102994C2 (pl)
WO (1) WO2008116149A2 (pl)
ZA (1) ZA201205868B (pl)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3960855A1 (en) * 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
WO2004087760A1 (en) * 2003-04-01 2004-10-14 Inserm (Institut National De La Sante De La Reche Rche Medicale) Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions
EP1941275B1 (en) 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
BRPI0906261A2 (pt) * 2008-03-31 2015-07-07 Genentech Inc "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
EP2401300B1 (en) * 2009-02-25 2018-01-10 Academia Sinica ANTI-C[epsilon]mX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES
AU2014203008B2 (en) * 2009-02-25 2016-03-31 Academia Sinica Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes
AU2010241706B2 (en) 2009-04-29 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ERG monoclonal antibodies
EP2427497B1 (fr) 2009-05-07 2016-12-07 Stallergenes Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
EP2384766A1 (en) * 2010-05-03 2011-11-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel antibody to a carbonic anhydrase
US10017762B2 (en) 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
RU2578468C2 (ru) 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
US9795618B2 (en) * 2014-02-28 2017-10-24 University Of Cincinnati Methods and compositions for suppressing IgE-mediated anaphylaxis
US10086005B2 (en) 2011-04-12 2018-10-02 University Of Cincinnati Methods for suppressing allergic reactions
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
RS63930B1 (sr) 2011-10-28 2023-02-28 Prothena Biosciences Ltd Humanizovana antitela koja prepoznaju alfa-sinuklein
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
DK2807188T3 (da) 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
KR20140119777A (ko) * 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
WO2013158274A1 (en) * 2012-04-20 2013-10-24 Academia Sinica ANTI-MIGE ANTIBODIES THAT BIND TO THE JUNCTION BETWEEN CH4 AND CεMX DOMAINS
EP2849723B1 (en) 2012-05-18 2018-05-02 Genentech, Inc. High-concentration monoclonal antibody formulations
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
US10543278B2 (en) 2012-09-12 2020-01-28 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
CN105143260A (zh) * 2013-03-13 2015-12-09 中央研究院 特异于人类膜结合型IgE的CEMX上的新颖抗原决定部位的抗体及其用于治疗IgE介导的疾病的用途
MX368259B (es) * 2013-04-16 2019-09-25 Genentech Inc Variantes de pertuzumab y su evaluacion.
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
CN105324746B (zh) * 2013-06-19 2019-08-13 索尼公司 显示控制设备、显示控制方法和程序
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
AR098155A1 (es) 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
TW201532513A (zh) * 2014-01-10 2015-09-01 Alfur Fu-Hsin Hung 能產生比小鼠ＩgＥ量高出許多的人源化ＩgＥ之基因轉殖動物
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
DK3157951T3 (da) * 2014-06-17 2020-08-17 Academia Sinica Humaniserede anti-ige-antistoffer, der tværbinder cd23 på b-lymfocytter, men ikke sensibiliserer mastceller
JP2017536102A (ja) * 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
SI3226897T1 (sl) 2014-12-05 2021-08-31 Memorial Sloan Kettering Cancer Center Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
MY191537A (en) 2014-12-05 2022-06-30 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
TWI691512B (zh) * 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
US10294304B2 (en) * 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
US20180186896A1 (en) 2015-07-07 2018-07-05 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
US10758612B2 (en) 2015-07-15 2020-09-01 Washington University Antibodies to tumor associated complex N-glycans with terminal GlcNAcβ residues and methods of use thereof
JP6068582B2 (ja) * 2015-08-07 2017-01-25 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｂリンパ球上のヒトｍＩｇＥに結合可能な抗ＣεｍＸ抗体
MA46681A (fr) * 2016-01-28 2019-09-11 Janssen Biotech Inc Anticorps bispécifiques anti-tnf-alpha/il-17a antibodies et anticorps anti-tnf-alpha et leurs procédés d'utilisation
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
US11708421B2 (en) 2016-07-18 2023-07-25 Ramot At Tel-Aviv University Ltd. Modular platform for targeted therapeutics
US11384156B2 (en) 2016-07-25 2022-07-12 The Nemours Foundation Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
WO2018089335A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
AU2017382281B2 (en) 2016-12-22 2024-07-11 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
US11298314B2 (en) 2017-04-21 2022-04-12 Ami Pharm Co., Ltd. Injectable composition for localized fat reduction without pain, edema, and side effects, and method for preparing same
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
WO2019085902A1 (en) 2017-10-31 2019-05-09 Fountain Biopharma Inc. Treating ige-mediated allergic diseases
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
MX2020004568A (es) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
AU2018362747B2 (en) * 2017-11-07 2025-08-14 Hubit Genomix, Inc. Method for primary prevention of allergic disorders during infancy through IgE-class-specific immunosuppression
WO2019135668A1 (ko) 2018-01-08 2019-07-11 주식회사 프로젠 Ige fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법
KR20220098056A (ko) 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CA3114668A1 (en) * 2018-10-01 2020-04-09 The Board Of Trustees Of The Leland Stanford Junior University High specificity and sensitivity immunosorbent diagnostic assays with simultaneous resolution of multiple antibody isotypes
MA54078A (fr) 2018-11-01 2021-09-15 Juno Therapeutics Inc Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
CA3132587A1 (en) * 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN111411066B (zh) * 2020-03-30 2022-08-23 江南大学 一种双途径复合产神经氨酸枯草芽孢杆菌及构建方法
EP4206226A4 (en) * 2020-08-31 2024-10-16 Medytox Inc. Anti-vegf hexameric antibody and composition comprising same
KR20260042217A (ko) 2023-07-13 2026-03-30 인히브릭스 바이오사이언스, 인크. IgE 결합 단백질 및 이의 용도
CN117467016B (zh) * 2023-12-27 2024-03-12 北京索莱宝科技有限公司 人IgA的抗体、抗体组合及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714759A (en) * 1985-12-02 1987-12-22 Whitaker Jr Robert B Immunotoxin therapy of allergy
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5079344A (en) 1989-06-21 1992-01-07 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgA
US5089603A (en) 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
US5422258A (en) 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US5690934A (en) 1987-12-31 1997-11-25 Tanox Biosystems, Inc. Peptides relating to the extracellular membrane-bound segment of human alpha chain
US5342924A (en) * 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
AU618317B2 (en) 1987-12-31 1991-12-19 Tanox Biosystems, Inc. Unique antigenic epitopes on ige-bearing b lymphocytes
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US5260416A (en) 1987-12-31 1993-11-09 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgE
US5362643A (en) 1989-06-21 1994-11-08 Tanox Biosystems Antibodies to epitopes present on membrane-bound but not secreted IGA
US5484907A (en) 1989-06-21 1996-01-16 Tanox Biosystems, Inc. Nucleotides coding for the extracellular membrane-bound segment of IgA
US5254671A (en) 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
US5514776A (en) 1987-12-31 1996-05-07 Tanox Biosystems, Inc. Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5252467A (en) 1987-12-31 1993-10-12 Tanox Biosystems, Inc. Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE
US5614611A (en) 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5274075A (en) * 1987-12-31 1993-12-28 Tanox Biosystems, Inc. Newly identified human epsilon immunoglobulin peptides and related products
US5428133A (en) 1987-12-31 1995-06-27 Tanox Biosystems, Inc. Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
US5310875A (en) 1989-06-21 1994-05-10 Tanox Biosystems, Inc. Peptides corresponding to membrane-bound IgA
CA2074089C (en) * 1990-01-23 2001-04-10 Tse-Wen Chang Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992017207A1 (en) 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
AU4012095A (en) 1994-10-25 1996-05-15 United Biomedical Inc. Synthetic ige membrane anchor peptide immunogens for the treatment of allergy
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
WO2004070011A2 (en) 2003-02-01 2004-08-19 Tanox, Inc. HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
CN1926149A (zh) * 2004-02-02 2007-03-07 泰勒公司 新的IgE表位的鉴别
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
EP1941275B1 (en) * 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE

Also Published As

Publication number Publication date
ES2478242T3 (es) 2014-07-21
UA102994C2 (ru) 2013-09-10
AU2008228778B2 (en) 2014-05-22
HRP20140661T1 (hr) 2014-10-10
US20090010924A1 (en) 2009-01-08
WO2008116149A3 (en) 2008-11-06
CY1115257T1 (el) 2017-01-04
EP2132230A2 (en) 2009-12-16
JP5723594B2 (ja) 2015-05-27
MA31312B1 (fr) 2010-04-01
TWI464178B (zh) 2014-12-11
PT2132230E (pt) 2014-07-17
US8618274B2 (en) 2013-12-31
AR066198A1 (es) 2009-08-05
CR11035A (es) 2009-12-03
RS53402B (sr) 2014-10-31
EP2132230B1 (en) 2014-04-16
PE20140771A1 (es) 2014-07-07
EP2644621A1 (en) 2013-10-02
CN101679528B (zh) 2013-11-06
PE20090726A1 (es) 2009-06-23
DK2132230T3 (da) 2014-06-30
ECSP099645A (es) 2009-10-30
US20120144512A1 (en) 2012-06-07
US8071097B2 (en) 2011-12-06
NZ580553A (en) 2012-05-25
CN101679528A (zh) 2010-03-24
RU2500686C2 (ru) 2013-12-10
KR20100015754A (ko) 2010-02-12
AU2008228778A1 (en) 2008-09-25
MX2009010092A (es) 2010-02-09
US20120177635A1 (en) 2012-07-12
EP2644621B1 (en) 2017-12-13
US20120178127A1 (en) 2012-07-12
HK1194743A1 (zh) 2014-10-24
CL2008000839A1 (es) 2008-09-26
BRPI0808291A2 (pt) 2018-12-11
TW200848432A (en) 2008-12-16
WO2008116149A2 (en) 2008-09-25
CO6241138A2 (es) 2011-01-20
CN103554263B (zh) 2016-09-28
US8586040B2 (en) 2013-11-19
RU2009138932A (ru) 2011-04-27
SI2132230T1 (sl) 2014-07-31
ZA201205868B (en) 2014-04-30
JP2010521989A (ja) 2010-07-01
IL200752A0 (en) 2010-05-17
US20120149881A1 (en) 2012-06-14
KR101555068B1 (ko) 2015-10-06
JP2017048190A (ja) 2017-03-09
JP2015017103A (ja) 2015-01-29
US20140115729A1 (en) 2014-04-24
US8632775B2 (en) 2014-01-21
CN103554263A (zh) 2014-02-05
CA2681341A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
ZA201205868B (en) Apoptotic anti-ige antibodies binding the membrane-bound ige
IL201156A0 (en) ANTI-IgE ANTIBODIES AND USES THEREOF
IL204537A0 (en) Modified antibody constant region
GB0708002D0 (en) Antibodies
ZA201003025B (en) Anti-hepcidin antibodies and uses thereof
ZA201003578B (en) Wise binding antibodies and epitopes
PL2146745T3 (pl) Pięcioswoiste przeciwciało
LT2436696T (lt) Anti-beta-amiloido antikūnas ir jo panaudojimas
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
GB2450937B (en) Component with tuned frequency response
IL208045A0 (en) Antibody against the csf-1r
ZA201004133B (en) Antigen binding proteins
SI2200700T1 (sl) Nova protitelesa
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
HRP20130494T1 (en) Anti-ilt7 antibody
IL185366A0 (en) Antibody
IL201983A (en) Antibody against pan nrpa
IL205073A0 (en) Anti-bst2 antibody
PL2174921T3 (pl) Materiał wiążący dla struktury typu plastra miodu i struktura typu plastra miodu wykorzystująca ten materiał
EP2146936A4 (en) ELECTRO-OSMOTIC DEHYDRATOR
GB0702888D0 (en) Novel Antibodies
GB0517487D0 (en) Antibodies
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES